Abstract: An apparatus for recording the amount of medicament ejected from an injection device includes a processor to receive information from a primary sensor and a secondary sensor and a memory. The primary sensor is configured to detect information displayed or generated by said injection device and to generate output corresponding thereto. The secondary sensor is configured to detect ejection of medicament from said injection device. The processor is configured to process the output generated by the primary sensor and to record in the memory information indicative of an amount of medicament ejected from said injection device only when the processor determines, on the basis of information received from the secondary sensor, that more than a predetermined amount of medicament has been ejected.

Abstract: A supplemental device for attachment to an injection device, the supplemental device is presented having a processor arrangement; and a quantity determiner for determining a quantity of medicament that has been delivered, wherein the quantity determiner has a sensor arranged to detect movement of a drive screw of the injection device during medicament delivery.

Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The disclosure provides a two-chamber carpule comprising two-chambers adapted to be joined together. Each chamber is adapted to contain a medicament component. The carpule further comprises a bevel arranged on a circumference of at least one of the chambers in a transition area. The bevel extends from one chamber to the other chamber.

Abstract: The present invention relates to a modified cellulosic fiber that comprises anionic moieties in an amount of more than 0.25 mol/kg of dry fiber and has applied theron a polymeric modifying agent in an amount of from 0.5 wt. % to 5.0 wt. %, based on dry fiber, the polymeric modifying agent comprising cationic moieties with a charge of at least 1.5 meq per gram of polymer and the molar ratio of anionic moieties to cationic moieties contained in the fiber is in the range of from 1:1 to 25:1. The fiber according to the present invention is characterized in that the anionic moieties are incorporated in the fiber and are from carboxymethylcellulose, and that the polymeric modifying agent comprising cationic moieties is selected from the group consisting of polydiallyldimethylammonium chloride (poly-DADMAC), poly(acrylamide-co-diallyldimethylammonium chloride) (PAM-DADMAC) and mixtures thereof. The invention furthermore relates to a nonwoven product or fabric comprising the modified cellulosic fiber. (FIG.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: An iron-chromium-aluminum alloy with improved heat resistance, low chromium vaporization rate and good processability, comprising (in % by mass), 2.0 to 4.5% Al, 12 to 25% Cr, 1.0 to 4% W, 0.25 to 2.0% Nb, 0.05 to 1.2% Si, 0.001 to 0.70% Mn, 0.001 to 0.030% C, 0.0001 to 0.05% Mg, 0.0001 to 0.03% Ca, 0.001 to 0.030% P, max. 0.03% N, max. 0.01% S, remainder iron and the usual melting-related impurities.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R5, A1, A2, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds having the general formula (Ia) or (Ib), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease, in particular influenza.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, m and n are as described herein, compositions including the compounds and methods of using the compounds.